Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer.

McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Lam TNA, Li Y, Sun C, Li Y, Schmandt R, Wu JY, Hu L, Liang Y, Peng G, Jonasch E, Menter D, Yates MS, Kopetz S, Lu KH, Broaddus R, Mills GB, Sahni N, Lin SY.

Cancer Cell. 2020 Mar 16;37(3):371-386.e12. doi: 10.1016/j.ccell.2020.01.011. Epub 2020 Feb 27.

PMID:
32109374
2.

Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression.

Kwan SY, Au-Yeung CL, Yeung TL, Rynne-Vidal A, Wong KK, Risinger JI, Lin HK, Schmandt RE, Yates MS, Mok SC, Lu KH.

Cancers (Basel). 2020 Jan 2;12(1). pii: E118. doi: 10.3390/cancers12010118.

3.

Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2019 May 15;25(10):3194. doi: 10.1158/1078-0432.CCR-19-1132. No abstract available.

PMID:
31092618
4.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2018 Jul 2;128(7):3199. doi: 10.1172/JCI122301. Epub 2018 May 29. No abstract available.

5.

Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer.

Yates MS, Coletta AM, Zhang Q, Schmandt RE, Medepalli M, Nebgen D, Soletsky B, Milbourne A, Levy E, Fellman B, Urbauer D, Yuan Y, Broaddus RR, Basen-Engquist K, Lu K.

Cancer Prev Res (Phila). 2018 Aug;11(8):477-490. doi: 10.1158/1940-6207.CAPR-17-0398. Epub 2018 May 1.

6.

Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.

Ring KL, Yates MS, Schmandt R, Onstad M, Zhang Q, Celestino J, Kwan SY, Lu KH.

Int J Gynecol Cancer. 2017 Jun;27(5):854-862. doi: 10.1097/IGC.0000000000000960.

7.

Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN.

Iglesias DA, Zhang Q, Celestino J, Sun CC, Yates MS, Schmandt RE, Lu KH.

Oncology. 2017;92(2):109-114. doi: 10.1159/000450615. Epub 2016 Dec 9.

8.

Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment.

Onstad MA, Schmandt RE, Lu KH.

J Clin Oncol. 2016 Dec 10;34(35):4225-4230. Epub 2016 Nov 7. Review.

9.

Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.

Soliman PT, Zhang Q, Broaddus RR, Westin SN, Iglesias D, Munsell MF, Schmandt R, Yates M, Ramondetta L, Lu KH.

Gynecol Oncol. 2016 Dec;143(3):466-471. doi: 10.1016/j.ygyno.2016.10.011. Epub 2016 Oct 13.

10.

Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1.

Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK, Schmandt R, Lu KH, Mok SC.

Nat Commun. 2016 Mar 29;7:11150. doi: 10.1038/ncomms11150.

11.

Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53.

Co NN, Iglesias D, Celestino J, Kwan SY, Mok SC, Schmandt R, Lu KH.

Cancer. 2014 Nov 15;120(22):3457-68. doi: 10.1002/cncr.28854. Epub 2014 Jul 16.

12.

CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity.

Zhang Q, Schmandt R, Celestino J, McCampbell A, Yates MS, Urbauer DL, Broaddus RR, Loose DS, Shipley GL, Lu KH.

Gynecol Oncol. 2014 Apr;133(1):83-9. doi: 10.1016/j.ygyno.2013.12.006.

13.

The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.

Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH.

Int J Gynecol Cancer. 2014 May;24(4):713-7. doi: 10.1097/IGC.0000000000000118.

14.

Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.

Iglesias DA, Yates MS, van der Hoeven D, Rodkey TL, Zhang Q, Co NN, Burzawa J, Chigurupati S, Celestino J, Bowser J, Broaddus R, Hancock JF, Schmandt R, Lu KH.

Mol Cancer Ther. 2013 Dec;12(12):2847-56. doi: 10.1158/1535-7163.MCT-13-0439. Epub 2013 Sep 27.

15.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2013 May;123(5):2119-30. doi: 10.1172/JCI65425. Epub 2013 Apr 15.

16.

Chemopreventive effects of metformin on obesity-associated endometrial proliferation.

Zhang Q, Celestino J, Schmandt R, McCampbell AS, Urbauer DL, Meyer LA, Burzawa JK, Huang M, Yates MS, Iglesias D, Broaddus RR, Lu KH.

Am J Obstet Gynecol. 2013 Jul;209(1):24.e1-24.e12. doi: 10.1016/j.ajog.2013.03.008. Epub 2013 Mar 15.

17.

Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.

Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC.

Clin Cancer Res. 2013 Feb 15;19(4):809-20. doi: 10.1158/1078-0432.CCR-12-2736. Epub 2013 Jan 23.

18.

Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors.

Klopp AH, Zhang Y, Solley T, Amaya-Manzanares F, Marini F, Andreeff M, Debeb B, Woodward W, Schmandt R, Broaddus R, Lu K, Kolonin MG.

Clin Cancer Res. 2012 Feb 1;18(3):771-82. doi: 10.1158/1078-0432.CCR-11-1916. Epub 2011 Dec 13.

19.

Understanding obesity and endometrial cancer risk: opportunities for prevention.

Schmandt RE, Iglesias DA, Co NN, Lu KH.

Am J Obstet Gynecol. 2011 Dec;205(6):518-25. doi: 10.1016/j.ajog.2011.05.042. Epub 2011 Jun 7. Review.

20.

Regulation of tumor angiogenesis by EZH2.

Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK.

Cancer Cell. 2010 Aug 9;18(2):185-97. doi: 10.1016/j.ccr.2010.06.016.

21.

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK.

Cancer Biol Ther. 2010 Feb;9(3):176-82. Epub 2010 Feb 16.

22.

EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.

Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK.

J Natl Cancer Inst. 2009 Sep 2;101(17):1193-205. doi: 10.1093/jnci/djp231. Epub 2009 Jul 29.

23.

Therapeutic Targeting of ATP7B in Ovarian Carcinoma.

Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK.

Clin Cancer Res. 2009 Jun 1;15(11):3770-80. doi: 10.1158/1078-0432.CCR-08-2306. Epub 2009 May 26.

24.

Estrous cycle modulates ovarian carcinoma growth.

Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings NB, Nick AM, Langley RR, Schmandt R, Lutgendorf SK, Cole SW, Sood AK.

Clin Cancer Res. 2009 May 1;15(9):2971-8. doi: 10.1158/1078-0432.CCR-08-2525. Epub 2009 Apr 21.

25.

Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis.

Nanjundan M, Cheng KW, Zhang F, Lahad J, Kuo WL, Schmandt R, Smith-McCune K, Fishman D, Gray JW, Mills GB.

Mol Oncol. 2008 Aug;2(2):164-81. doi: 10.1016/j.molonc.2008.05.001. Epub 2008 May 10.

26.

Dicer, Drosha, and outcomes in patients with ovarian cancer.

Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK.

N Engl J Med. 2008 Dec 18;359(25):2641-50. doi: 10.1056/NEJMoa0803785. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.

27.

Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.

Wong KK, Lu KH, Malpica A, Bodurka DC, Shvartsman HS, Schmandt RE, Thornton AD, Deavers MT, Silva EG, Gershenson DM.

Int J Gynecol Pathol. 2007 Oct;26(4):404-9.

PMID:
17885490
28.

Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8+ cells in ovarian ascites.

Ishiyama S, Matsueda S, Jones LA, Efferson C, Celestino J, Schmandt R, Ioannides CG, Tsuda N, Chang DZ.

Int J Oncol. 2007 Apr;30(4):889-98.

PMID:
17332928
29.

Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma.

Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK.

Cancer Res. 2007 Feb 15;67(4):1757-68.

30.

Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.

Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK.

Cancer Biol Ther. 2006 Dec;5(12):1708-13. Epub 2006 Dec 30.

PMID:
17106249
31.

Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.

Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.

J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70.

PMID:
17077358
32.

Identification of a novel splice variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive functions.

Nanjundan M, Zhang F, Schmandt R, Smith-McCune K, Mills GB.

Oncogene. 2007 Apr 19;26(18):2574-84. Epub 2006 Oct 30.

PMID:
17072347
33.

Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.

Merritt WM, Thaker PH, Landen CN Jr, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Schmandt R, Gershenson DM, Kinch MS, Sood AK.

Cancer Biol Ther. 2006 Oct;5(10):1357-60. Epub 2006 Oct 31.

PMID:
16969087
34.

Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2006 Aug 15;12(16):4916-24. Erratum in: Clin Cancer Res. 2019 May 15;25(10):3194.

35.

The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary.

Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK, Gershenson DM.

Cancer Biol Ther. 2006 Sep;5(9):1136-41. Epub 2006 Sep 28.

PMID:
16855388
36.

Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.

Han LY, Landen CN Jr, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, Sood AK.

J Clin Oncol. 2006 Feb 10;24(5):755-61. Epub 2005 Dec 27.

PMID:
16380413
37.

Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.

Halder J, Landen CN Jr, Lutgendorf SK, Li Y, Jennings NB, Fan D, Nelkin GM, Schmandt R, Schaller MD, Sood AK.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8829-36.

38.

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK.

Cancer Res. 2005 Aug 1;65(15):6910-8.

39.

Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.

Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH.

Gynecol Oncol. 2004 Oct;95(1):32-6.

PMID:
15385107
40.

Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.

Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr.

Clin Cancer Res. 2004 May 15;10(10):3291-300.

41.

Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk.

Oh JC, Wu W, Tortolero-Luna G, Broaddus R, Gershenson DM, Burke TW, Schmandt R, Lu KH.

Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):748-52.

42.

A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets.

Ramondetta LM, Burke TW, Jhingran A, Schmandt R, Bevers MW, Wolf JK, Levenback CF, Broaddus R.

Gynecol Oncol. 2003 Sep;90(3):529-36.

PMID:
13678720
43.

Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.

Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM.

Cancer. 2003 Aug 15;98(4):758-64.

44.

Overexpression of kallikrein 10 in epithelial ovarian carcinomas.

Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC Jr, Gershenson DM, Schmandt R.

Gynecol Oncol. 2003 Jul;90(1):44-50.

PMID:
12821340
45.

beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma.

Lee CM, Shvartsman H, Deavers MT, Wang SC, Xia W, Schmandt R, Bodurka DC, Atkinson EN, Malpica A, Gershenson DM, Hung MC, Lu KH.

Gynecol Oncol. 2003 Mar;88(3):363-8.

PMID:
12648588
46.

Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.

Jazaeri AA, Lu K, Schmandt R, Harris CP, Rao PH, Sotiriou C, Chandramouli GV, Gershenson DM, Liu ET.

Mol Carcinog. 2003 Feb;36(2):53-9.

PMID:
12557260
47.

Genetic analysis of early- versus late-stage ovarian tumors.

Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC Jr, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI.

Cancer Res. 2001 Aug 1;61(15):5895-904.

48.

Should therapy of ovarian cancer patients be individualized based on underlying genetic defects?

Mills GB, Schmandt R, Gershenson D, Bast RC.

Clin Cancer Res. 1999 Sep;5(9):2286-8. No abstract available.

49.
50.

Mammalian NUMB is an evolutionarily conserved signaling adapter protein that specifies cell fate.

Verdi JM, Schmandt R, Bashirullah A, Jacob S, Salvino R, Craig CG, Program AE, Lipshitz HD, McGlade CJ.

Curr Biol. 1996 Sep 1;6(9):1134-45.

Supplemental Content

Loading ...
Support Center